SCHEMBL1342879

SCHEMBL1342879

COc1ccccc1ON(C(=O)CC(=O)Nc1nc(CC(=O)O)c(Sc2ncc[nH]2)s1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CSNK1D P48730 1/20 0.34
KDM4E B2RXH2 3/20 0.33
HPGD P15428 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GCK P35557 1/20 0.33
LMNA P02545 3/20 0.33
MAPT P10636 3/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CASP1 P29466 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MPO P05164 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342966 0.96 CSNK1D (0.35) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1340467 0.87 GCK (0.43) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1342841 0.86 MAPT (0.32) MEN1KMT2AKDM4EGCKMAPT
SCHEMBL1341898 0.85 NPC1 (0.40) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1342875 0.83 TSHR (0.41) NPC1RAB9ATSHRMEN1KMT2A
SCHEMBL1343019 0.82 GCK (0.44) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1341249 0.81 GCK (0.33) MAPK1MEN1KMT2AKDM4EALDH1A1
SCHEMBL1341773 0.81 CSNK1D (0.40) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1342214 0.80 GCK (0.44) NPC1RAB9ATSHRMAPK1MEN1
SCHEMBL1342054 0.80 NPC1 (0.41) NPC1RAB9ATSHRMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 NPC1 2201/4885RAB9A 3353/4885TSHR 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.